Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd. (BWAY) generates a steady flow of news centered on its Deep TMS™ neurostimulation technology, regulatory developments, clinical research, and financial performance. As a company focused on noninvasive brain stimulation for mental health disorders, BrainsWay frequently announces updates related to major depressive disorder, obsessive-compulsive disorder, smoking addiction, and emerging indications such as Alcohol Use Disorder.
News items for BrainsWay often cover FDA clearances and label expansions, including accelerated Deep TMS protocols for MDD and indications that extend treatment to adolescent patients aged 15 to 21. The company also reports on payer coverage decisions, such as new or expanded medical policies from insurers that reimburse Deep TMS depression therapy for adults and adolescents, and coverage of its SWIFT™ accelerated protocol. These updates provide insight into how access to Deep TMS is evolving across different patient populations and geographies.
Investors following BWAY can also expect clinical research and grant-related announcements, including NIH-funded studies evaluating accelerated Deep TMS protocols for Alcohol Use Disorder and stimulant use disorders, as well as company-sponsored trials using the Deep TMS 360™ multichannel system. In addition, BrainsWay issues news on strategic investments, such as its minority-stake investment in Neurolief and stakes in mental health providers, and on financial results that highlight revenue trends, installed base growth, and multi-year customer agreements.
The BrainsWay news page on Stock Titan aggregates these updates so readers can track regulatory milestones, payer coverage changes, clinical trial progress, strategic partnerships, and quarterly financial disclosures related to BWAY stock. This makes it a useful reference for monitoring how the company’s Deep TMS platform and broader neuromodulation strategy are developing over time.
BrainsWay Ltd. (NASDAQ: BWAY) has appointed Professor Markus Heilig, an expert in addiction and anxiety treatment, to its scientific advisory board. Professor Heilig, who has a notable background in neuroscience and previously directed clinical research at the National Institute on Alcohol Abuse and Alcoholism, will guide BrainsWay's research strategies, particularly in Deep TMS™ therapy. This appointment underscores BrainsWay's commitment to advancing neuroscience amid urgent mental health needs and aims to enhance treatment efficacy for mental health disorders.
BrainsWay Ltd. (NASDAQ: BWAY) announced promising research data validating the durability and cost-effectiveness of Deep TMS for treating Obsessive-Compulsive Disorder (OCD). Key findings from studies published in peer-reviewed journals indicate that 86.7% of patients experienced treatment durability of over one year, with significant reductions in functional disability. Additionally, Deep TMS was shown to be a cost-effective alternative compared to other treatment methods, addressing a significant healthcare burden exceeding $7 billion annually in the U.S.
BrainsWay Ltd. has published findings from a randomized, placebo-controlled pilot study on its Deep TMS™ System aimed at reducing alcohol consumption and cravings in adults with Alcohol Use Disorder (AUD). Conducted with 46 subjects, results showed a significant decrease in heavy drinking days—2.9 for the treatment group compared to 10.6 for placebo. The study highlights the potential of Deep TMS in addressing AUD, particularly amidst rising cases exacerbated by the pandemic. No serious adverse events were reported, marking a promising step for future treatments in this area.
BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, announced that CEO Christopher von Jako, Ph.D., will present at the Sidoti December Micro-Cap Investor Conference on December 9, 2021, at 10 am EST. The event, occurring December 8-9, will also feature one-on-one investor meetings. BrainsWay's Deep TMS technology is FDA-cleared for major depressive disorder, OCD, and smoking addiction. For more details, visit www.brainsway.com.
BrainsWay Ltd. (BWAY) reported a 34% revenue growth year-over-year, reaching $8.1 million for Q3 2021, driven by high demand for its Deep TMS therapy. The company achieved a total revenue of $21.2 million for the first nine months, marking a 41% increase compared to the same period in 2020. The installed base of Deep TMS systems rose by 22% to 717 units. Regulatory clearance was obtained for Deep TMS therapy for treating anxious depression, adding to its portfolio. Despite a net loss of $1.8 million in Q3, cash reserves increased to $55.3 million.
BrainsWay Ltd. (NASDAQ: BWAY), a leader in noninvasive neurostimulation for mental health, will report its Q3 2021 financial results on November 17, 2021, before U.S. market opening. The company plans to host a conference call at 8:30 AM ET to discuss the results and update on operations. BrainsWay is recognized for its Deep TMS™ technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The call will be available for replay for 30 days.
BrainsWay Ltd. (NASDAQ: BWAY) has appointed Dr. Zafiris Daskalakis to its scientific advisory board, enhancing its expertise in brain stimulation. Dr. Daskalakis, Chair of Psychiatry at UCSD, brings extensive research knowledge and over 450 publications in neurophysiology and psychiatric disorders. This strategic addition aims to strengthen BrainsWay’s growth and clinical impact as it seeks to expand the application of its Deep TMS™ technology for mental health treatment. CEO Christopher von Jako emphasized the importance of Dr. Daskalakis’s insights in navigating the company's future.
BrainsWay Ltd. (NASDAQ: BWAY) has released promising data from a pivotal clinical trial published in World Psychiatry, supporting its Deep TMS™ treatment for smoking addiction. Conducted across 12 U.S. and 2 Israeli sites with 262 chronic smokers, the trial showed over 25% of patients achieving a minimum of 4 weeks of abstinence. The treatment, which is FDA-cleared, demonstrated significant reductions in smoking behavior. BrainsWay is engaged in a controlled market release to refine its business model and gather post-marketing data.
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 – BrainsWay (NASDAQ: BWAY) announced that CEO Christopher von Jako will present at two investment conferences in September. The first is the Oppenheimer & Co. Fall Healthcare Life Sciences & Medtech Virtual Summit from September 20-23, with a presentation on September 22 at 3:45 PM ET. The second is the Cantor Fitzgerald Global Healthcare Conference from September 27-30, with a presentation on September 27 at 3:20 PM ET. Investors can arrange meetings with management during these events.
BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 – BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation for mental health, will have its CEO, Christopher von Jako, present and hold investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is recognized for its Deep TMS™ technology, with three FDA-clearances for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. With ongoing clinical trials, BrainsWay aims to expand global access to its innovative treatments.